Zepbound and Wegovy are the two heavyweights of the GLP-1 weight loss world, and if you are trying to decide between them, you are asking the right question. Both are FDA-approved specifically for chronic weight management, both require weekly injections, and both cost a small fortune at retail price. But they are not the same drug, and the differences matter.

:::takeaway

  • Zepbound vs Wegovy: Zepbound and Wegovy are the two heavyweights of the GLP-1 weight loss world, and if you are trying to decide between them, you are asking th...
  • Cost varies significantly between brand-name and compounded versions of these medications
  • Side Effects Comparison Both medications cause similar gastrointestinal side effects, especially during the dose titration period when your body is adjusting.
  • Consult a healthcare provider before starting any medication.

:::

I have spent months digging into the clinical data, talking to providers across our directory of 9,580+ GLP-1 clinics, and reading through patient experiences. Here is the honest breakdown.

Zepbound vs Wegovy at a Glance

Feature Zepbound (tirzepatide) Wegovy (semaglutide)
Manufacturer Eli Lilly Novo Nordisk
Drug class Dual GIP/GLP-1 receptor agonist GLP-1 receptor agonist
FDA approval November 2023 (weight loss) June 2021 (weight loss)
Administration Weekly subcutaneous injection Weekly subcutaneous injection
Dose range 2.5 mg to 15 mg 0.25 mg to 2.4 mg
Average weight loss 15-22.5% of body weight 12-14.9% of body weight
List price ~$1,060/month ~$1,349/month
Savings program As low as $25/month with commercial insurance As low as $0-$25/month with commercial insurance

How They Work: One Target vs Two

This is the fundamental difference and it matters more than most articles will tell you.

Wegovy contains semaglutide, which targets the GLP-1 receptor. It mimics the incretin hormone GLP-1, which slows gastric emptying, reduces appetite, and helps regulate blood sugar. One receptor, one mechanism. It does that job extremely well.

Zepbound contains tirzepatide, which targets both GLP-1 and GIP receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that plays a role in fat metabolism and energy balance. Activating both pathways appears to produce stronger metabolic effects than GLP-1 alone.

Think of it this way: Wegovy hits one switch. Zepbound hits two. The clinical data suggests that second switch makes a meaningful difference.

Weight Loss Results: The Numbers

Let me put the clinical trial data side by side because the difference is significant.

SURMOUNT-1 Trial (Zepbound/Tirzepatide)

  • Participants: 2,539 adults with obesity or overweight
  • Duration: 72 weeks
  • Results by dose:
    • 5 mg: 15.0% body weight loss
    • 10 mg: 19.5% body weight loss
    • 15 mg: 22.5% body weight loss
  • Placebo group: 3.1% body weight loss

STEP 1 Trial (Wegovy/Semaglutide)

  • Participants: 1,961 adults with obesity or overweight
  • Duration: 68 weeks
  • Results:
    • 2.4 mg: 14.9% body weight loss
  • Placebo group: 2.4% body weight loss

At the highest doses, Zepbound produced about 50% more weight loss than Wegovy. For someone weighing 250 pounds, that is roughly the difference between losing 37 pounds on Wegovy and losing 56 pounds on Zepbound.

That said, these are averages. Some people respond better to semaglutide than tirzepatide, and vice versa. Your genetics, starting weight, diet, and activity level all play a role.

Side Effects Comparison

Both medications cause similar gastrointestinal side effects, especially during the dose titration period when your body is adjusting. Here is how they compare:

Side Effect Zepbound (15 mg) Wegovy (2.4 mg)
Nausea 24% 44%
Diarrhea 21% 30%
Vomiting 12% 24%
Constipation 11% 24%
Abdominal pain 7% 6%
Injection site reactions 5% 3%

One thing worth noting: Wegovy shows higher rates of nausea and vomiting in clinical trials, but Zepbound patients report more diarrhea. Neither medication is pleasant during the first few weeks of dose increases, but most patients report that side effects become manageable after 4 to 6 weeks at a stable dose.

Both medications carry warnings about potential thyroid tumors (based on animal studies), pancreatitis, and gallbladder problems. These serious side effects are rare but worth discussing with your provider.

Dosing Schedule

Both medications are injected once per week, but the titration schedules differ:

Zepbound Dosing

  • Weeks 1-4: 2.5 mg
  • Weeks 5-8: 5 mg
  • Weeks 9-12: 7.5 mg (optional)
  • Weeks 13-16: 10 mg (optional)
  • Weeks 17+: 12.5 mg or 15 mg (optional)

Wegovy Dosing

  • Weeks 1-4: 0.25 mg
  • Weeks 5-8: 0.5 mg
  • Weeks 9-12: 1 mg
  • Weeks 13-16: 1.7 mg
  • Weeks 17+: 2.4 mg (maintenance)

Zepbound has more flexibility in its dosing. You can stay at 5 mg or 10 mg if the weight loss is adequate and you tolerate it well. Wegovy's titration is more linear, moving everyone toward the 2.4 mg maintenance dose.

Cost and Insurance

Here is where things get complicated and where most comparison articles leave you hanging.

Retail Pricing

  • Zepbound: ~$1,060/month (list price)
  • Wegovy: ~$1,349/month (list price)

Manufacturer Savings Programs

  • Zepbound: Eli Lilly's savings card can bring the cost to $25/month for commercially insured patients
  • Wegovy: Novo Nordisk's savings offer can reduce costs to $0-$25/month with eligible commercial insurance

Compounded Alternatives

If you cannot get insurance coverage for either brand-name medication, compounded versions of both active ingredients are available through telehealth providers. Based on our data from 15 telehealth providers, compounded options typically cost:

  • Compounded semaglutide: $99-$349/month
  • Compounded tirzepatide: $149-$499/month

Insurance Coverage

Coverage depends entirely on your specific plan. Here is what we know from our database of 9,580+ GLP-1 clinics:

  • 95.6% of clinics in our directory accept insurance
  • Both Zepbound and Wegovy are more likely to be covered when prescribed for patients with BMI 30+ or BMI 27+ with comorbidities
  • Medicare Part D will begin covering GLP-1 medications for weight loss in July 2026
  • Medicaid coverage varies by state

Which Should You Choose?

There is no universal right answer, but here is my take after analyzing the data.

Choose Zepbound if:

  • Maximum weight loss is your primary goal
  • You want dosing flexibility (the option to stay at a mid-range dose)
  • You have tried semaglutide and plateaued
  • Your insurance covers tirzepatide or you can access compounded tirzepatide affordably

Choose Wegovy if:

  • You want the medication with a longer track record (FDA-approved since 2021)
  • You are interested in cardiovascular benefits (the SELECT trial showed semaglutide reduced cardiovascular events by 20%)
  • Your insurance specifically covers Wegovy but not Zepbound
  • You tolerate semaglutide well and are already seeing results

The bottom line: If I had to pick one for a patient starting from scratch with no insurance preference, the clinical data favors Zepbound for pure weight loss. But Wegovy's cardiovascular benefits and longer safety track record make it a strong choice too. Either way, the best medication is the one your provider recommends based on your specific health profile and the one you can actually afford and access consistently.

Find a Provider

Ready to start treatment? Use our clinic directory to find a GLP-1 provider near you, or take our 2-minute quiz to get matched with a telehealth provider.

This article is for informational purposes only and is not medical advice. Consult a healthcare provider before starting any medication. Clinical trial results referenced from published SURMOUNT-1 and STEP 1 trial data.

:::warning

The right GLP-1 medication depends on your individual health profile, not just price or average weight loss numbers. Talk to your provider about your medical history, current medications, and treatment goals before making a decision.

:::

Other Medications to Consider

Zepbound and Wegovy are not your only options. Here is how other GLP-1 and weight loss medications compare:

  • Ozempic uses the same semaglutide as Wegovy but at a lower dose (up to 2 mg vs 2.4 mg). FDA-approved for type 2 diabetes, frequently prescribed off-label for weight loss.
  • Mounjaro is the diabetes version of Zepbound (same tirzepatide). Sometimes prescribed off-label for weight loss when Zepbound is not covered.
  • Saxenda is an older daily GLP-1 injection. Less effective than semaglutide or tirzepatide but may be covered by more insurance plans.
  • Rybelsus is an oral semaglutide tablet approved for diabetes, sometimes prescribed off-label.
  • Contrave is a non-GLP-1 oral weight loss medication (naltrexone/bupropion) that works differently and is significantly cheaper.
  • Foundayo (orforglipron) is Eli Lilly's new oral GLP-1 pill, launched April 2026 at $149 per month.

For detailed cost comparison across all of these, see our cost guide or cheapest providers list.

Sources

  1. Jastreboff, A.M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity." SURMOUNT-1 Trial. New England Journal of Medicine, 2022.
  2. Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." STEP 1 Trial. New England Journal of Medicine, 2021.
  3. Lincoff, A.M., et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." SELECT Trial. New England Journal of Medicine, 2023.
  4. GLP1 Clinics directory data, April 2026. 9,580+ verified providers across 50 states.